Google+ Facebook Twitter Twitter

“Tumour-uninformed” blood test

A team of scientists has evaluated the first “tumour-uninformed” test that detects cancer DNA circulating in the blood of patients following treatment.

Unlike previous tests for circulating tumour DNA (ctDNA) in the blood, this test, called Guardant Reveal, does not require knowledge of the particular mutations that were present in the patient’s tumour.

The team evaluated the tumour-uninformed ctDNA assay to detect residual cancer cells in patients who underwent surgery for colorectal cancer.

Instead of relying on DNA sequencing of individual patients’ tumours, the approach looked for known cancer-specific alterations.

When the researchers analysed ctDNA results from 84 patients and examined how accurately the results correlated with cancer recurrence, they found that this “plasma-only” approach was similar in sensitivity and specificity to tumour-informed approaches.

Image credit | Science Photo Library


Related Articles

The neonatal blood film

As at any other time in life, examination of a blood film in a neonate can be very informative. It is important that films are interpreted in the context of the clinical details and the blood count. It is also necessary to consider the period of gestation of the neonate at birth, since what is normal differs in term and preterm babies, particularly for those born before 28 weeks’ gestation.

My lab: a busy multi-site facility

Biomedical Scientist Team Leader Liam Morrissey gives a guided tour of blood sciences at the University Hospitals of Leicester NHS Trust.

Review, refresh and reimagine

A look back at how the Blood Stocks Management Scheme has evolved over the last two decades, some recent achievements, and what is planned for the next 20 years.

Covid-19 and haemostasis screening: the expected and the unexpected

Senior Biomedical Scientist Clare Wigley and colleagues take us through how their lab processes and workflow changed during the waves of the COVID-19 pandemic.